
Please try another search
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human ERT for the treatment of gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; and CAN204 to treat Duchenne muscular dystrophy. It has a license agreement with Mirum Pharmaceuticals, Inc. for the development, manufacture, and commercialization of Livmarli. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.
Name | Age | Since | Title |
---|---|---|---|
James Qun Xue | 54 | 2018 | Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board |
Peng Kuan Chan | 60 | 2021 | Independent Non-Executive Director |
Richard James Gregory | 66 | 2020 | Independent Non-Executive Director |
Lan Hu | 55 | 2022 | Independent Non-Executive Director |
Mark A. Goldberg | 70 | - | Member of Strategic Advisory Board |
James Arthur Geraghty | 70 | 2018 | Independent Non-Executive Director |
Guangping Gao | - | 2020 | Member of Strategic Advisory Board |
Anthony Amato | - | 2022 | Member of Scientific Advisory Board |
Sushrut Waikar | - | 2022 | Member of Scientific Advisory Board |
Robert Colvin | - | 2022 | Member of Scientific Advisory Board |
Jean Francis | - | 2022 | Member of Scientific Advisory Board |
Brian Weinshenker | - | 2022 | Member of Scientific Advisory Board |
Richard Polisson | - | 2022 | Member of Scientific Advisory Board |
Wei Zhao | 45 | 2025 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review